P. Murali Doraiswamy
Professor of Psychiatry and Behavioral Sciences
Murali Doraiswamy MBBS FRCP is professor of psychiatry and professor in medicine at the Duke University School of Medicine where he is a highly respected physician neuroscientist at the Duke Institute for Brain Sciences. He specializes in the areas of brain health and personalized medicine and leads a clinical trials unit in developing novel personal diagnostics and therapeutics for cognitive enhancement and mental well-being. Prof Doraiswamy has been an advisor to leading government agencies, businesses and advocacy groups. He has served as the chair of the World Economic Forum’s Global Agenda Council on Brain Research and lectured at leading global forums to advance the forefront of neuroscience research. Moreover as co-author of a popular book The Alzheimer’s Action Plan and co-author on more than 350 publications, he has received several awards in recognition of his scientific work and his involvement in pivotal landmark trials that have helped develop many modern neurotherapeutics. Additionally, he is a leading advocate for increasing funding for brain and behavioral research to help address great looming challenges in society posed by modern developments in the 21st century. His research has been featured in media outlets such as BBC, The New York Times, Scientific American, The Wall Street Journal, National Public Radio, CBS Evening news, The Dr Oz Show, Oprah, and TIME. He has appeared in acclaimed documentaries such as (Dis)Honesty: The Truth about Lies and Mysteries of the Brain.
Genetic Modulations of Morbidity Compression: A Population-Based Study awarded by National Institutes of Health (Investigator). 2020 to 2025
Racial and Geographic Disparities in Risk and Survival of Alzheimer's Disease and Related Dementias: Effects of Over/UnderDiagnosis and Disease Severity awarded by National Institutes of Health (Senior Investigator). 2019 to 2024
Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)" awarded by National Institutes of Health (Preceptor). 2020 to 2023
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-AD awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Evaluating Effects in the Relationship between Traumatic Brain Injury and Alzheimer's Disease: Epidemiological Determinants, Their Health-Related Causes and the Resulting Disparities awarded by United States Army Medical Research Acquisition Activity (Senior Investigator). 2020 to 2023
Gut Liver Brain Biochemical Axis in Alzheimer's Disease awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to Treatment awarded by National Institutes of Health (Co Investigator). 2018 to 2023
Predicting prebiotic effects on human microbiota, behavior, and cognition. awarded by Office of Naval Research (Collaborator). 2018 to 2021
Does rifaximin improve cognition in patients with Alzheimer's disease?" using Manufacturer's drug XIFAXAN awarded by Bausch Health US LLC (Co Investigator). 2019 to 2021
A Clinical-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology awarded by Avid Radiopharmaceuticals Inc (Principal Investigator). 2015 to 2021
Bernath, Megan M., et al. “Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers.” Neurology, vol. 94, no. 20, May 2020, pp. e2088–98. Pubmed, doi:10.1212/WNL.0000000000009436. Full Text
Arnold, Matthias, et al. “Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.” Nat Commun, vol. 11, no. 1, Mar. 2020, p. 1148. Pubmed, doi:10.1038/s41467-020-14959-w. Full Text
Blumenthal, James A., et al. “Longer Term Effects of Diet and Exercise on Neurocognition: 1-Year Follow-up of the ENLIGHTEN Trial.” J Am Geriatr Soc, vol. 68, no. 3, Mar. 2020, pp. 559–68. Pubmed, doi:10.1111/jgs.16252. Full Text
Sabbagh, M. N., et al. “Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting.” J Prev Alzheimers Dis, vol. 7, no. 3, 2020, pp. 171–78. Pubmed, doi:10.14283/jpad.2020.22. Full Text
Sabbagh, M. N., et al. “Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies.” J Prev Alzheimers Dis, vol. 7, no. 3, 2020, pp. 158–64. Pubmed, doi:10.14283/jpad.2020.19. Full Text
Horgusluoglu-Moloch, Emrin, et al. “Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways.” Sci Rep, vol. 9, no. 1, Oct. 2019, p. 14498. Pubmed, doi:10.1038/s41598-019-50507-3. Full Text
Nho, Kwangsik, et al. “Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.” Jama Netw Open, vol. 2, no. 7, July 2019, p. e197978. Pubmed, doi:10.1001/jamanetworkopen.2019.7978. Full Text Open Access Copy
Pontecorvo, Michael J., et al. “A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.” Brain, vol. 142, no. 6, June 2019, pp. 1723–35. Pubmed, doi:10.1093/brain/awz090. Full Text
Goudey, Benjamin, et al. “A blood-based signature of cerebrospinal fluid Aβ1-42 status.” Sci Rep, vol. 9, no. 1, Mar. 2019, p. 4163. Pubmed, doi:10.1038/s41598-018-37149-7. Full Text
Privitera, Gregory J., et al. “Differential food intake and food choice by depression and body mass index levels following a mood manipulation in a buffet-style setting.” J Health Psychol, vol. 24, no. 2, Feb. 2019, pp. 199–208. Pubmed, doi:10.1177/1359105316650508. Full Text
Harenberg, S., et al. “Knowledge-guided maximal clique enumeration.” Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 10086 LNAI, 2016, pp. 604–18. Scopus, doi:10.1007/978-3-319-49586-6_43. Full Text
Doraiswamy, P. Murali, et al. “Preimplantation Genetic Diagnosis (PGD) for Familial Alzheimer's Disease Due To PSEN1 Mutation.” Annals of Neurology, vol. 76, WILEY-BLACKWELL, 2014, pp. S90–S90.
Hochstetler, Helen, et al. “Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S136–S136. Crossref, doi:10.1016/j.jagp.2012.12.180. Full Text
Witte, Michael, et al. “Florbetapir PET Imaging Predicts Postmortem Amyloid Burden in Alzheimer's Disease Despite Presence of Other Neuropathologies.” The American Journal of Geriatric Psychiatry, vol. 21, no. 3, Elsevier BV, 2013, pp. S138–39. Crossref, doi:10.1016/j.jagp.2012.12.183. Full Text
Sheldon, F. C., et al. “Disruption of Functional Brain Connections in Alzheimer's Disease.” Journal of Nuclear Medicine, vol. 51, no. 5, SOC NUCLEAR MEDICINE INC, 2010, pp. 828–29.
Doraiswamy, P. Murali, et al. “In Cognitively Healthy and Mildly Impaired Individuals Florbetapir F 18 PET Measures of Amyloid Deposition Correlate with the Degree of Functional Impairment Assessed Six Months Later.” Neurology, vol. 74, no. 9, LIPPINCOTT WILLIAMS & WILKINS, 2010, pp. A338–A338.
Doraiswamy, P. Murali, et al. “Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 283S-284S.
Kaddurah-Daouk, Rima, et al. “Metabolomic mapping of schizophrenia and atypical antipsychotic effects.” Biological Psychiatry, vol. 61, no. 8, ELSEVIER SCIENCE INC, 2007, pp. 164S-164S.
Szarfman, A., et al. “Risperidone and pituitary tumors: a pharmacovigilance study.” Bipolar Disorders, vol. 7, BLACKWELL PUBLISHING, 2005, pp. 116–17.
Pomara, N., et al. “Elevated plasma A beta(1-42) in geriatric depression.” Biological Psychiatry, vol. 57, no. 8, ELSEVIER SCIENCE INC, 2005, pp. 200S-200S.